Swimming Against the Nucleotides
Advances in cell and gene therapy have led to a spate of novel treatments for inherited retinal disease. But with each breakthrough comes new dilemmas...
Robert MacLaren | | Quick Read
Gene therapies are no longer just hype – they provide tangible benefits to real patients, today. What disease will next fall to this powerful modality? For a clue, look at the biggest gene therapy trial in the world.
Gene therapy has been hyped for many years, in many therapy areas – but for now, it may be ocular disease that benefits most. Regulators have already approved a gene therapy for Leber Congenital Amaurosis (LCA), and similar products are currently being developed for several other diseases of the eye. Some of these are now in clinical trials and attracting commercial interest. Overall, the field is moving very quickly, and it’s an exciting time to be involved, not least in my own field: gene therapies for choroideremia and X-linked retinitis pigmentosa.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine